Stock Financial Ratios, Dividends, Split History

NOG / Northern Oil and Gas, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)352.52
Enterprise Value ($M)1,009.39
Book Value ($M)-488.78
Book Value / Share-3.81
Price / Book-0.27
NCAV ($M)-1,006.23
NCAV / Share-7.85
Price / NCAV-0.34
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 62,408,855
Common Stock Shares Outstanding 66,791,633
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Diluted Shares Outstanding 62,408,855
Common Shares Outstanding 65,944,133
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.02
Return on Assets (ROA)-0.02
Return on Equity (ROE)0.02
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio0.99
Income Statement (mra) ($M)
Other Sales Revenue Net23,314.00
Oil And Gas Sales Revenue223,963,010.00
Operating Income60.49
Net Income-9.19
Earnings Per Share Basic-0.15
Earnings Per Share Diluted-0.15
Cash Flow Statement (mra) ($M)
Cash From Operations72.97
Cash from Investing-119.24
Cash from Financing72.97
Identifiers and Descriptors
Central Index Key (CIK)1104485
Related CUSIPS
665531959 665531909

Split History

Stock splits are used by Northern Oil and Gas, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Here's Why You Should Buy Northern Oil Stock

12h zacks
On Jun 22, Northern Oil and Gas, Inc. (NOG - Free Report) was upgraded to a Zacks Rank #1 (Strong Buy). (44-0)

New Strong Buy Stocks for June 22nd

16h zacks
Delphi Technologies PLC (DLPH - Free Report) : This company that design, development, and manufacture of integrated powertrain technologies has seen the Zacks Consensus Estimate for its current year earnings increasing 2.9% over the last 60 days. (13-0)

BRIEF-Northern Oil And Gas Reports Qtrly Adjusted Net Income Per Share Of $0.17

2018-05-07 reuters

U.S. Shale: NAV Analysis Of Williston Basin (Bakken) E&Ps

2018-05-04 seekingalpha
WLL, OAS, NOG and AXAS all have relatively small asset bases, especially when compared to Permian Basin E&Ps. (185-0)

ConocoPhillips (COP) Completes 2018 Winter Appraisal Program

2018-04-17 zacks
ConocoPhillips (COP - Free Report) has wrapped up its 2018 winter exploration and appraisal program in Alaska. The outcome of the program holds promise and the company intends to expand its track record of operational success and value creation in Alaska. Initially, ConocoPhillips had planned to drill five wells on the Western North Slope. This included two appraisal wells of the Willow Discovery announced in January 2017 and three exploration wells. (48-0)

CUSIP: 665531109